US approves a third daily pill for breast cancer with an ESR1 mutation

Giredestrant, taken with everolimus, has won US approval for advanced ER-positive breast cancer with an ESR1 mutation. It is the third daily tablet in a drug class where women once relied on monthly injections.

4 min read

Giredestrant, taken with everolimus, has won US approval for advanced ER-positive breast cancer with an ESR1 mutation. It is the third daily tablet in a drug class where women once relied on monthly injections.

Content note: this article discusses advanced breast cancer.

The US Food and Drug Administration has approved giredestrant, sold as Wilserdly, for adults with advanced breast cancer that carries an ESR1 mutation. The cancer must be oestrogen receptor (ER)-positive and HER2-negative, and must have grown despite hormone treatment. Patients take a 30 mg tablet once a day, with or without food, alongside everolimus, another tablet. The decision came on 16 November, four weeks early.

ESR1 is the gene that makes the oestrogen receptor. Mutations in it can let a tumour keep growing despite hormone therapy. Doctors find them with a blood test, and the FDA authorised FoundationOne Liquid CDx alongside the drug.

What the trial found

Approval rests on the phase III evERA trial, reported in the New England Journal of Medicine. Among 207 people with ESR1-mutated tumours, median progression-free survival was 10 months with giredestrant and everolimus. It was 5.5 months with standard hormone therapy plus everolimus, a hazard ratio of 0.38. Across all 373 participants, the medians were 8.8 and 5.5 months.

Overall survival data are still immature. In the ESR1-mutated group, the survival difference is not yet statistically significant (hazard ratio 0.62, confidence interval 0.38 to 1.02).

What a daily tablet changes

Fulvestrant, an injection, was for many years the only drug that blocks and breaks down the oestrogen receptor. Its US label sets the dose as two 5 mL injections, one in each buttock. A health professional gives them on days 1, 15 and 29, then once a month. In one trial on the label, 12% of patients on the standard dose reported pain at the injection site.

A tablet taken at home removes those clinic appointments and needles. Nurses interviewed by Oncology Nursing News in 2024 said patients prefer oral drugs because they don't have to come in as often. NICE, which assesses medicines for England, recorded in its 2025 appraisal of elacestrant that the tablet "would be easily administered".

Fulvestrant also has a dose ceiling. Authors of a 2024 review in Frontiers in Oncology say the approved dose does not fully suppress the receptor. Raising it would mean more injections.

Giredestrant was never compared head to head with fulvestrant. In the trial's comparison arm, 141 people took exemestane, an aromatase inhibitor tablet, and 39 received fulvestrant. So the longer control of the cancer came against mostly oral treatment, and the convenience gain applies to women who would otherwise have injections.

The FDA lists mouth sores (stomatitis), rash, fatigue, diarrhoea, muscle pain, nausea and pneumonitis, a lung inflammation, as common side effects of the combination. Stomatitis affected 47% of patients on giredestrant, a similar rate to the comparison arm, where everyone also took everolimus. Side effects led 17% to stop treatment, against 11.8% in the comparison arm.

How it compares with other tablets

Elacestrant, the first oral drug in this class, won FDA approval in January 2023. Imlunestrant followed in September 2025, and in September 2026 the agency cleared it with abemaciclib. Giredestrant is the only one of the three approved with everolimus. In England, NICE recommends elacestrant for some people whose cancer has progressed after hormone therapy and a CDK4/6 inhibitor.

US reviewers assessed giredestrant through Project Orbis, a scheme that shares cancer drug reviews with other regulators. Health Canada and Israel's Ministry of Health took part. No official source has yet given a price.

Looking for more guidance?

The American Society of Clinical Oncology (ASCO) recommends routine ESR1 testing when ER-positive, HER2-negative metastatic breast cancer recurs or progresses on hormone therapy. Its 2023 guideline update prefers a blood test to a tissue sample. Women with advanced breast cancer can ask their oncologist about ESR1 testing and which oral or injected options suit them.

In the UK, Breast Cancer Now's nurses answer its free helpline on 0808 800 6000. Elsewhere, a national cancer charity or your treatment team can point you to support.

The FDA is due to decide by 30 November whether giredestrant can also treat early breast cancer after surgery, based on the lidERA trial.

This content is for information only and does not replace advice from a qualified health professional.

Header image: Adolfo Félix on Unsplash

Get the week's essential women's health journalism

Evidence-based reporting, delivered to your inbox every week. No hype, no fads.